• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • Mallinckrodt Completes Acquisition of Ocera Therapeutics, OCR-002 americanpharmaceuticalreview
    December 12, 2017
    Mallinckrodt has closed the acquisition of Ocera Therapeutics, a clinical-phase biopharmaceutical company focused on the development and commercialization of novel therapeutic drugs for orphans and other serious liver diseases that have not been met
  • Mallinckrodt to Acquire Ocera Therapeutics, OCR-002 americanpharmaceuticacreview
    November 03, 2017
    The FDA granted OCR-002 its Orphan Drug Designation, and the resulting seven years' exclusivity would be applied upon first approval of the drug.

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service